Q1 Earnings Forecast for Metagenomi Issued By HC Wainwright

Metagenomi, Inc. (NASDAQ:MGX - Free Report) - Equities research analysts at HC Wainwright upped their Q1 2025 earnings estimates for Metagenomi in a report released on Thursday, April 3rd. HC Wainwright analyst M. Kapoor now expects that the company will post earnings per share of ($0.47) for the quarter, up from their previous estimate of ($0.56). HC Wainwright has a "Buy" rating and a $7.00 price target on the stock. The consensus estimate for Metagenomi's current full-year earnings is ($2.46) per share. HC Wainwright also issued estimates for Metagenomi's Q2 2025 earnings at ($0.51) EPS, Q3 2025 earnings at ($0.54) EPS, Q4 2025 earnings at ($0.58) EPS and FY2025 earnings at ($2.10) EPS.

Separately, Wells Fargo & Company cut their price objective on shares of Metagenomi from $25.00 to $20.00 and set an "overweight" rating on the stock in a report on Tuesday, March 18th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $13.00.

Metagenomi Stock Performance

Shares of MGX stock traded up $0.10 on Monday, hitting $1.48. The stock had a trading volume of 239,654 shares, compared to its average volume of 759,731. The stock's 50 day moving average is $1.92 and its 200-day moving average is $2.34. The firm has a market capitalization of $55.33 million, a price-to-earnings ratio of -0.56 and a beta of -0.27. Metagenomi has a 52-week low of $1.23 and a 52-week high of $9.67.

Metagenomi (NASDAQ:MGX - Get Free Report) last issued its quarterly earnings data on Monday, March 17th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.01). Metagenomi had a negative net margin of 134.27% and a negative return on equity of 43.23%. The firm had revenue of $9.61 million during the quarter, compared to analyst estimates of $13.18 million. During the same period last year, the business earned ($20.05) EPS.

Institutional Trading of Metagenomi

A number of hedge funds have recently made changes to their positions in the stock. Pinnacle Wealth Planning Services Inc. acquired a new stake in Metagenomi in the fourth quarter valued at $92,000. Nuveen Asset Management LLC acquired a new stake in shares of Metagenomi in the 4th quarter valued at about $228,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Metagenomi by 338.7% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,193 shares of the company's stock worth $55,000 after purchasing an additional 11,730 shares during the last quarter. Focus Partners Wealth bought a new position in shares of Metagenomi during the fourth quarter worth about $99,000. Finally, Bank of America Corp DE grew its stake in Metagenomi by 482.9% in the fourth quarter. Bank of America Corp DE now owns 21,113 shares of the company's stock worth $76,000 after purchasing an additional 17,491 shares in the last quarter.

Metagenomi Company Profile

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.